EMEA updates Zometaâ label to include longer-term efficacy data on prevention of bone complications in advanced cancers
Basel, 12 June 2003 - Novartis announced today that it has received approval from the European Agency for the Evaluation of Medicinal Products (EMEA) to expand the current marketing authorization for Zometa® (zoledronic acid) to include data on long-term treatment for patients with advanced cancers that have spread to the bone.
Please see full press release under the following link: